“`html
Moderna (MRNA) will report its third-quarter earnings on November 6, 2025, with Zacks Consensus Estimates predicting sales of $860 million and a loss of $2.15 per share. This indicates a significant decline compared to the previous year. Over the last month, loss per share estimates for 2025 have widened from $9.50 to $9.74.
In recent earnings history, Moderna has beaten estimates in the past four quarters with an average surprise of 37.78%. The company expects to make approximately $762 million from its COVID-19 vaccines, a notable decline due to reduced demand. Additionally, sales of its RSV vaccine, mResvia, are estimated at only $30 million, far below competing products from GSK and Pfizer.
Year-to-date, Moderna’s shares have dropped 40%, underperforming both the industry (which grew by 12%) and the S&P 500. The company’s current price-to-sales ratio stands at 3.14, above the industry average of 2.33.
“`
